A Single Lipiflow Treatment Increases Soft Contact Lens Wearing Time And Reduces Lid Wiper Epitheliopathy And Dry Eye Symptoms

Title A Single Lipiflow Treatment Increases Soft Contact Lens Wearing Time And Reduces Lid Wiper Epitheliopathy And Dry Eye Symptoms
Author, Co-Author Donald Korb, Caroline Blackie
Topic Cornea, Contact Lenses, and Refractive Technology
Year
2014
Day
Thursday, November 13, 2014 - 03:00
Program Number
145031
Room
Four Seasons Ballroom
Affiliation
Korb Associates
Abstract Purpose: To evaluate the one-month post treatment effects of a single LipiFlow treatment in symptomatic soft contact lens (SCL) wearing patients with reduced SCL wearing time and lid wiper epitheliopathy (LWE).

Methods: A retrospective analysis of eligible SCL wearing patients with MGD and LWE was performed on 19 eligible patient records (Test: n=11, Control: n=8). Inclusion criteria: Symptomatic for dry eye (Standard Patient Evaluation of Eye Dryness (SPEED) score ≥ 6); report of reduced SCL wearing time; SCL fit and care system ruled out as reasons for the reduced wearing time; LWE ≥ 0.5 (scale of 0 – 4). At baseline: SPEED score was measured; SCL wearing time was recorded; fluorescein and lissamine green were used to diagnose LWE. Test patients had received a single LipiFlow treatment at the baseline exam. Control patients had received instructions for artificial lubrication (saline drops) twice daily at the baseline exam. All patients had been re-evaluated at one-month post LipiFlow treatment/ baseline exam.

Results: The mean age of patients: Test group = 42.2±16.0, Control group = 39.8±13.3. One month post LipiFlow treatment, test patients showed significantly: reduced dry eye symptoms (10.1±3.2 to 6.2±3.7, p<0.005); longer SCL wearing time (4.8±2.6 to 8.2±3.0, p<0.0001); and reduced LWE (1.5±0.7 to 0.6±0.5, p=0.006). Patients in the control group showed no significant change in all three parameters: Symptoms: 9.8±2.6 to 8.8±2.9, p>0.05; SCL wearing time: 4.8±2.0 to 5.6±2.1, p>0.05; and LWE: 1.4±0.7 to 1.3±0.8, p>0.05.

Conclusions: The results of this retrospective study suggest that a single LipiFlow treatment can significantly increase SCL wearing time, reduce LWE and dry eye symptoms in symptomatic SCL wearing patients.
Affiliation of Co-Authors TearScience
Outline